Skip to Content

PT Kalbe Farma Tbk KLBF

Morningstar Rating
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

KLBF is trading at a 578% premium.
Price
IDR 1,574.19
Fair Value
IDR 3,786.23
Uncertainty
High
1-Star Price
IDR 1,929.63
5-Star Price
IDR 5,687.13
Economic Moat
Vxbbf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KLBF is a good fit for your portfolio.

Trading Information

Previous Close Price
Day Range
52-Week Range
Bid/Ask
/
Market Cap
Volume/Avg
/

Key Statistics

Price/Earnings (Normalized)
25.30
Price/Sales
2.35
Dividend Yield (Trailing)
1.98%
Dividend Yield (Forward)
1.98%
Total Yield
1.98%

Company Profile

PT Kalbe Farma Tbk is a drug manufacturing company that focuses on prescription pharmaceuticals, over-the-counter drugs, energy drinks, and nutrition products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. Majority of the company's gross profits are derived from the distribution and logistics segments. The company operates in Indonesia but has operations across various ASEAN countries, Nigeria, and South Africa.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Core
Total Number of Employees
13,062

Comparables

Valuation

Metric
KLBF
EPMT
TSPC
Price/Earnings (Normalized)
25.308.938.77
Price/Book Value
3.230.821.10
Price/Sales
2.350.210.67
Price/Cash Flow
18.979.505.90
Price/Earnings
KLBF
EPMT
TSPC

Financial Strength

Metric
KLBF
EPMT
TSPC
Quick Ratio
2.451.272.01
Current Ratio
4.312.322.75
Interest Coverage
48.5059.6517.76
Quick Ratio
KLBF
EPMT
TSPC

Profitability

Metric
KLBF
EPMT
TSPC
Return on Assets (Normalized)
10.44%6.28%9.85%
Return on Equity (Normalized)
13.70%9.68%14.61%
Return on Invested Capital (Normalized)
12.05%9.52%11.54%
Return on Assets
KLBF
EPMT
TSPC
See how this stock stacks up to its competitors with Morningstar Investor

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
FxmtdftxnRjm$834.9 Bil
Johnson & Johnson
JNJ
KtccxrcfhTxph$350.3 Bil
Merck & Co Inc
MRK
MwpyyrfxtVzb$327.9 Bil
AbbVie Inc
ABBV
YqzddhcNfcy$297.7 Bil
AstraZeneca PLC ADR
AZN
DrgffvfnvPrts$247.3 Bil
Roche Holding AG ADR
RHHBY
PllgzcdytXkpz$223.9 Bil
Novartis AG ADR
NVS
VlskpkywVqzv$216.8 Bil
Amgen Inc
AMGN
KzvjjxvlmRkhv$160.2 Bil
Pfizer Inc
PFE
DnbpqdfqfVgzz$156.0 Bil
Sanofi SA ADR
SNY
QtqdgppHzj$116.1 Bil

Sponsor Center